Lactococcus garvieae is considered to be a rare pathogen with low virulence in humans. We herein experienced an unusual case of multi-valve infective endocarditis caused by L. garvieae in an elderly woman who had undergone bioprosthetic mitral valve replacement due to severe mitral stenosis with rheumatic etiology. The patient was successfully treated with cardiac surgery after teicoplanin antimicrobial therapy failure followed by ceftriaxone treatment. L. garvieae was confirmed as the pathogen through 16S rRNA sequencing. To the best of our knowledge, this is the first case to indicate an effective treatment for infective endocarditis caused by L. garvieae in the Republic of Korea.
Introduction
In 1985, Lactococcus garvieae, formerly grouped with Streptococcus, was re-classified as Lactococcus based on a genetic analysis; it is one of eight species of facultative anaerobic, catalase-negative, Gram-positive cocci (1) . This organism is well known in aquaculture as a fish pathogen, however, there are few reports in the literature of infections caused by L. garvieae in both immunocompromised and immunocompetent humans, including patients with infective endocarditis (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) , osteomyelitis (19) (20) (21) , liver abscess (22) , cholecystitis (23) , and peritonitis (24) . Based on its low virulence in humans, L. garvieae has generally been considered to be an opportunistic pathogen in immunocompromised hosts.
However, its role in human clinical settings has not been clearly defined; an increasing numbers of patients in the clinical setting are immunocompromised due to acquired immune deficiency syndrome, cancer chemotherapy, organ transplants, and old age. Furthermore, due to insufficient clinical data about the efficacy of antimicrobial agents, therapeutic antibiotic options have not been established and there are currently no guidelines for standardized antibiotic susceptibility breakpoints for L. garvieae isolates. We herein describe what we believe to be the first reported Korean case of a patient with infective endocarditis caused by L. garvieae who was successfully treated with antibiotics and cardiac surgery.
Case Report
A 75-year-old woman presented to our hospital with a three-day history of dyspnea [New York Heart Association (NYHA) class III]. She had a history of a mitral valve replacement three years prior due to severe mitral stenosis with rheumatic etiology. Her current medications included cilostazol, amiodarone, digoxin, and warfarin. Of note, she ate fresh seafood several times per month. She was admitted for progressive heart failure without a fever or chills. On admission, her heart rate was 84 beats/min, blood pressure was 120/80 mmHg, and her body temperature was 36.9 . The patient's body weight was 44 kg and body mass index was 18.6 kg/m 2 . A physical examination revealed a previously , and rifampin (600 mg/day) were prescribed as empirical antibiotic therapy. After receiving the staining results, the patient was started on teicoplanin (400 mg/day) after an initial loading dose of 400 mg/12 h administered three times. However, therapeutic drug monitoring (TDM) data for teicoplanin were unavailable because teicoplanin TDM is not routinely performed in our hospital. A MicroScan MICroSTREP plus panel was used to determine antimicrobial susceptibility and measure the minimum inhibitory concentrations (MICs), revealing susceptibility to penicillin (0.12 μg/mL), amoxicillin/ clavulanate (0.5/0.25 μg/mL), ceftriaxone (0.25 μg/mL), cefotaxime (0.25 μg/mL), meropenem (0.06 μg/mL), vancomycin (1 μg/mL), and levofloxacin (1 μg/mL) and resistance to clindamycin (>0.5 μg/mL (26) .
Under the clinical diagnosis of infective endocarditis, intravenous teicoplanin (400 mg, once daily) was administered for 14 days. However, pulmonary edema visible on chest Xrays steadily worsened and her serum CRP levels increased to 134.0 mg/L. The patient required intravenous furosemide. Follow-up TTE showed increased echogenic material 35 mm in diameter on the prosthetic mitral valve. Follow-up blood cultures taken after three days of antibiotic therapy were negative for L. garvieae. On the 17th day of admission, the patient underwent cardiac surgery (aortic and mitral valve bioprosthesis replacement). The intra-operative findings showed fresh vegetation that had invaded three leaflets of the bioprosthetic mitral valve ( Figure A) . Vegetation 3 mm in diameter was attached to the ventricular side of the left coronary cusp of the native aortic valve. A pathologic examination of the mitral valve revealed a thickened prosthetic valve containing vegetation with numerous polymorphonuclear leukocytes ( Figure B) . Gram staining of the tissue revealed paired clusters of Gram-positive cocci and coccobacillary forms within vegetation on both the mitral and aortic valves. However, tissue cultures of the valves were sterile, presumably due to the preceding 17 days of antibiotic therapy. According to these findings, the patient was started on ceftriaxone (2 g/day) immediately after cardiac surgery. The patient was discharged after completing the 26-day intravenous ceftriaxone treatment. At the 6-month follow-up visit after completion of antibiotic therapy, the patient was free of L. garvieae endocarditis.
Discussion
Over the last decades, L. garvieae has progressively spread in numerous countries and has been identified as the causative agent of lactococcosis outbreaks in several fish species (27, 28) . Due to improved molecular methodologies, these strains were revealed to originate not only in fish and dairy products, but also in meat products, vegetables, and cereals (29) . Along with this spread, L. garvieae has also been identified as a clinical pathogen in patients with infective endocarditis. Including our case, a total of 19 cases of infective endocarditis caused by L. garvieae have been reported in the literature (2-18). Eleven patients (57.9%) were men, and 15 (78.9%) were sixty years of age or older. Thirteen cases (68.4%) involved the native valve. Six patients (31.6%) underwent cardiac surgery due to infective endocarditis. Of these 19 cases, 4 (21.1%) died due to multi-organ failure, heart failure, or cerebral hemorrhage (Table) . None of these 4 cases underwent surgery.
In most routine clinical microbiology laboratories, misidentification of Lactococcus species as Enterococcus species may occur (14) . In automated identification systems, these isolates can result in a lack of identification of presumptive Enterococcus isolates. In such cases, the suspicion of Lactococcus species should be raised, particularly in blood cultures. Finally, molecular testing should be used to confirm the identity of L. garvieae (14) . Although infective endocarditis caused by L. garvieae is uncommon, the incidence of these cases may be underestimated due to difficulties in correctly identifying the isolates.
The previous 19 cases, including 4 patients with multivalve infective endocarditis, involved a total of 23 valves, including mitral (n=14), aortic (n=8), and tricuspid valves (n=1). Among these, native valves included 11 (78.6%) mitral and 4 (50.0%) aortic valves.
Previous reports speculated that L. garvieae infections might result from ingestion of contaminated food, especially raw fish, in patients with modified gastrointestinal tracts (13, 17, 18, 21, 23) . Our case was also exposed to raw fish and had underlying gastritis. Among the 19 reported cases, nine (47.4%) were associated with fish exposure, and 12 (63.2%) had gastrointestinal disorders (Table) . All previous cases, except a single German case, were reported from cities or countries on a peninsula or island or with contact with the sea.
There is little data on antimicrobial susceptibility of Lactococcus species, and formal CLSI interpretive criteria for Lactococcus do not currently exist. According to the criteria for Streptococcus species, clindamycin resistance is a feature of L. garvieae; this feature can be used to distinguish it from other Lactococcus species (30) . Of the previous 19 cases, 15 (78.9%) were administered ß-lactams and aminoglycoside antibiotic therapy. Of these 15 patients, 11 survived. The remaining 4 patients received antibiotic monotherapy, including vancomycin (n=2) or ampicillin (n=2) without mortality. Among these 4 patients, 3 (75%) underwent cardiac surgery. In our case, initial empirical antibiotic therapy for the prosthetic infective endocarditis was composed of ceftriaxone, gentamicin, and rifampin according to the clinical guideline (31) . After the staining results indicated infection with Gram-positive cocci, the patient was started on teicoplanin (400 mg/day) upon consideration of the patient's decreased renal function, in expectation of methicillin-resistant Staphylococcus aureus or multidrugresistant Streptococcus species. After L. garvieae was identified, teicoplanin was maintained continuously, because 5 of the previous 7 cases who received glycopeptides recovered from an illness in the literature review. However, the initial teicoplanin monotherapy resulted in treatment failure. This treatment failure might have been due to insufficient therapeutic blood levels. After cardiac surgery, the patient was started immediately on ceftriaxone (2 g/day), because no adjustment in the ceftriaxone dose is needed in renal impairment. It was also chosen based on the susceptibility test using an E-test.
Six (31.6%) patients of the previous 19 cases required surgical intervention. All those who underwent the surgical intervention after antibiotic treatment made satisfactory progress. Our patient required cardiac surgery upon admission due to heart failure and mobile vegetation >10 mm. However, she did not initially wish to undergo cardiac surgery. After persistent recommendation from our team, she finally agreed.
The clinical presentations of infective endocarditis might not include a fever over 38°C. Of the previous 19 cases, five (26.3%) were afebrile. This observation might be associated with old age, underlying disease, or less virulent and opportunistic pathogens.
In conclusion, L. garvieae should be considered as a causative pathogen of afebrile infective endocarditis in immunocompromised patients. With improved molecular tests and continued development of aquaculture, an increasing number of clinical cases of L. garvieae infection are expected. Furthermore, clinical guidelines for the treatment of L. garvieae infection should be established based on the standard criteria for antimicrobial susceptibility.
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